HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity1

Tat, the trans activation protein of HIV, is produced early upon infection to promote and expand HIV replication and transmission. However, Tat appears to also have effects on target cells, which may affect Ag recognition both during infection and after vaccination. In particular, Tat targets dendritic cells and induces their maturation and Ag-presenting functions, increasing Th1 T cell responses. We show in this work that Tat modifies the catalytic subunit composition of immunoproteasomes in B and T cells either expressing Tat or treated with exogenous biological active Tat protein. In particular, Tat up-regulates latent membrane protein 7 and multicatalytic endopeptidase complex like-1 subunits and down-modulates the latent membrane protein 2 subunit. These changes correlate with the increase of all three major proteolytic activities of the proteasome and result in a more efficient generation and presentation of subdominant MHC-I-binding CTL epitopes of heterologous Ags. Thus, Tat modifies the Ag processing and modulates the generation of CTL epitopes. This may have an impact on both the control of virally infected cells during HIV-1 infection and the use of Tat for vaccination strategies.

[1]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[2]  Luigi Buonaguro,et al.  HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.

[3]  M. Masucci,et al.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4 , 1993, Journal of virology.

[4]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[5]  R. Preissner,et al.  The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. , 2002, Journal of molecular biology.

[6]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[7]  A. Goldberg,et al.  Proteasome Subunits X and Y Alter Peptidase Activities in Opposite Ways to the Interferon-γ-induced Subunits LMP2 and LMP7* , 1996, The Journal of Biological Chemistry.

[8]  A. Goldberg,et al.  Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[10]  J. Monaco,et al.  β2 Subunit Propeptides Influence Cooperative Proteasome Assembly* , 2003, The Journal of Biological Chemistry.

[11]  M. Kasahara,et al.  The MHC class I ligand‐generating system: roles of immunoproteasomes and the interferon‐4gMY‐inducible proteasome activator PA28 , 1998, Immunological reviews.

[12]  L. Kaer,et al.  Immunoproteasome Assembly : Cooperative Incorporation of Interferon g ( IFN-g ) – inducible Subunits , 1997 .

[13]  S. Volinia,et al.  Supra-Agonist Peptides Enhance the Reactivation of Memory CTL Responses1 , 2000, The Journal of Immunology.

[14]  A. Borsetti,et al.  Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). , 2001, Vaccine.

[15]  F. Khanim,et al.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2 , 1993, Journal of virology.

[16]  J. Sodroski,et al.  Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. , 1990, Journal of acquired immune deficiency syndromes.

[17]  A. Canella,et al.  Selective amino acid substitutions of a subdominant Epstein‐Barr virus LMP2‐derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein‐Barr virus‐associated malignancies , 1999, European journal of immunology.

[18]  J. Whitton,et al.  Two Overlapping Subdominant Epitopes Identified by DNA Immunization Induce Protective CD8+ T-Cell Populations with Differing Cytolytic Activities , 2001, Journal of Virology.

[19]  J. Monaco,et al.  Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor β subunits , 1997 .

[20]  M. Masucci,et al.  HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. , 1993, Science.

[21]  G R Stark,et al.  Adenovirus E1A Down-regulates LMP2 Transcription by Interfering with the Binding of Stat1 to IRF1* , 2000, The Journal of Biological Chemistry.

[22]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[23]  Jonathan W. Yewdell,et al.  Immunoproteasomes Shape Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell Repertoire and Presentation of Viral Antigens , 2001, The Journal of experimental medicine.

[24]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[25]  Robert Huber,et al.  Contribution of Proteasomal β-Subunits to the Cleavage of Peptide Substrates Analyzed with Yeast Mutants* , 1998, The Journal of Biological Chemistry.

[26]  P. Kloetzel,et al.  Human immunodeficiency virus‐1 Tat protein interacts with distinct proteasomal α and β subunits , 2003 .

[27]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[28]  S. Burrows,et al.  Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.

[29]  A. Polack,et al.  Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. , 1998, Journal of immunology.

[30]  R. Tampé,et al.  Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. , 1997, Blood.

[31]  A. Goldberg,et al.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. , 1993, Nature.

[32]  S. Moretti,et al.  Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses1 , 2002, The Journal of Immunology.

[33]  J. Heeney,et al.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.

[34]  M. Masucci,et al.  c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells , 2001, Nature Cell Biology.

[35]  Yuntao Wu,et al.  Gene transcription in HIV infection. , 2003, Microbes and infection.

[36]  E. Coccia,et al.  Modulation of Human Immunodeficiency Virus 1 Replication by Interferon Regulatory Factors , 2002, The Journal of experimental medicine.

[37]  K. Ferrell,et al.  HIV-1 Tat Inhibits the 20 S Proteasome and Its 11 S Regulator-mediated Activation* , 1997, The Journal of Biological Chemistry.

[38]  L. Kaer,et al.  Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. , 1998 .

[39]  P. Kloetzel,et al.  Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes , 2000, The Journal of experimental medicine.

[40]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[41]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.